Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 28

1.

Conditional activation of RET/PTC3 and BRAFV600E in thyroid cells is associated with gene expression profiles that predict a preferential role of BRAF in extracellular matrix remodeling.

Mesa C Jr, Mirza M, Mitsutake N, Sartor M, Medvedovic M, Tomlinson C, Knauf JA, Weber GF, Fagin JA.

Cancer Res. 2006 Jul 1;66(13):6521-9.

2.

Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.

Quiros RM, Ding HG, Gattuso P, Prinz RA, Xu X.

Cancer. 2005 Jun 1;103(11):2261-8. Review.

3.

[Genetic factors predisposing to the development of papillary thyroid cancer].

Puzianowska-Kuźnicka M, Pietrzak M.

Endokrynol Pol. 2005 May-Jun;56(3):339-45. Review. Polish.

PMID:
16350729
4.

[The mitogen-activated protein kinase (MAPK) signaling pathway in papillary thyroid cancer. From the molecular bases to clinical practice].

Zafon C, Obiols G.

Endocrinol Nutr. 2009 Apr;56(4):176-86. doi: 10.1016/S1575-0922(09)70982-9. Epub 2009 Jun 11. Review. Spanish.

PMID:
19627734
5.

From nodule to differentiated thyroid carcinoma: contributions of molecular analysis in 2012.

Albarel F, Conte-Devolx B, Oliver C.

Ann Endocrinol (Paris). 2012 Jun;73(3):155-64. doi: 10.1016/j.ando.2012.03.002. Epub 2012 Apr 13. Review.

PMID:
22503804
6.

Clinical prognosis in BRAF-mutated PTC.

Puxeddu E, Moretti S.

Arq Bras Endocrinol Metabol. 2007 Jul;51(5):736-47. Review.

7.

BRAF mutation in papillary thyroid carcinoma: pathogenic role and clinical implications.

Tang KT, Lee CH.

J Chin Med Assoc. 2010 Mar;73(3):113-28. doi: 10.1016/S1726-4901(10)70025-3. Review.

8.

[BRAF gene mutation in thyroid cancer].

Kopczyńska E, Junik R, Tyrakowski T.

Pol Merkur Lekarski. 2006 Feb;20(116):210-3. Review. Polish.

PMID:
16708643
9.

[BRAF initiating mutations in the papillary thyroid carcinoma].

Rusinek D, Gubała E.

Endokrynol Pol. 2006 Jul-Aug;57(4):438-44. Review. Polish.

PMID:
17006850
10.

Alterations of the BRAF gene in thyroid tumors.

Ciampi R, Nikiforov YE.

Endocr Pathol. 2005 Fall;16(3):163-72. Review.

PMID:
16299399
11.

BRAF mutations in papillary thyroid carcinoma.

Wojciechowska K, Lewinski A.

Endocr Regul. 2006 Dec;40(4):129-38. Review.

PMID:
17201587
12.

RET/PTC rearrangements and BRAF mutations in thyroid tumorigenesis.

Ciampi R, Nikiforov YE.

Endocrinology. 2007 Mar;148(3):936-41. Epub 2006 Aug 31. Review.

PMID:
16946010
13.

[Fetal cell carcinogenesis hypothesis and the prospect of future laboratory tests].

Takano T.

Rinsho Byori. 2009 Aug;57(8):761-8. Review. Japanese.

PMID:
19764411
14.

[Molecular mechanism of thyroid carcinogenesis].

Yamashita S, Mitsutake N.

Nihon Rinsho. 2007 Nov;65(11):1959-65. Review. Japanese.

PMID:
18018555
15.

Genetic alterations in differentiated thyroid cancers.

Salehian B, Liu Z.

Endocr Metab Immune Disord Drug Targets. 2009 Sep;9(3):257-68. Epub 2009 Sep 1. Review.

PMID:
19594419
16.

Role of MAPK pathway oncoproteins in thyroid cancer pathogenesis and as drug targets.

Knauf JA, Fagin JA.

Curr Opin Cell Biol. 2009 Apr;21(2):296-303. doi: 10.1016/j.ceb.2009.01.013. Epub 2009 Feb 21. Review.

PMID:
19231149
17.

BRAF(V600E) and microenvironment in thyroid cancer: a functional link to drive cancer progression.

Nucera C, Lawler J, Parangi S.

Cancer Res. 2011 Apr 1;71(7):2417-22. doi: 10.1158/0008-5472.CAN-10-3844. Epub 2011 Mar 29. Review.

18.

Targeting BRAF in thyroid cancer.

Espinosa AV, Porchia L, Ringel MD.

Br J Cancer. 2007 Jan 15;96(1):16-20. Epub 2006 Dec 19. Review.

19.

Drug insight: Small-molecule inhibitors of protein kinases in the treatment of thyroid cancer.

Santoro M, Carlomagno F.

Nat Clin Pract Endocrinol Metab. 2006 Jan;2(1):42-52. Review.

PMID:
16932252
20.

[Genetic abnormality in thyroid cancers].

Yamashita S.

Nihon Rinsho. 2005 Oct;63 Suppl 10:159-62. Review. Japanese. No abstract available.

PMID:
16279621
Items per page

Supplemental Content

Write to the Help Desk